CB213

CB213 is a next-generation, fully human, multi-specific Humabody VH biologic that provides dual checkpoint blockade of programmed cell death protein 1 (PD-1) and lymphocyte-activation gene 3 (LAG3) on exhausted, dual-positive T cells, with an additional albumin-binding VHH domain for half-life extension and improved tissue penetration.[1][2] Built as an asymmetric LAG3-LAG3-PD1-HSA construct of linked VH domains with a predicted molecular weight of ~59 kDa, CB213 binds human and cynomolgus PD1 and LAG3 with high picomolar avidity, preferentially countering LAG3/MHC-II–mediated immunosuppression while also blocking PD1/PD-L1.[1][2] In preclinical models, CB213 enhanced proliferation and function of dysfunctional patient-derived T cells from non-small cell lung cancer (NSCLC) and produced robust tumour growth inhibition in a humanized PD1/LAG3 syngeneic colorectal cancer model, supporting its development as an immunotherapy for solid tumours resistant or refractory to PD-1 blockade alone.[1][2][4] CB213 is being developed by Crescendo Biologics in collaboration with Cancer Research UK, with Cancer Research UK’s Centre for Drug Development sponsoring a planned first-in-human phase 1 trial in patients with advanced solid tumours.[4][7]

Other names

CB213 HumabodyCB-213 HumabodyCB 213 Humabody